Leading The Way In Pediatric Endo-Cannabinoid Medicine
Phyto Therapeutic Medicine for Inflammatory Conditions
Initial 2.2 Million Square Feet of Cultivation
Exclusive Clinically Validated Formulations
Innovation in Skin Care and Anti-Aging Systems
Relevium’s CEO Provides an Open Shareholder Letter for 2020
by Olga Tkach | December 19, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide an open letter to its shareholders from the company’s Chief Executive Officer, Aurelio...Relevium Launches LeefyLyfe™ Organic Hemp Products in the US
by Olga Tkach | November 20, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the launch of LeefyLyfeTM Organics, a comprehensive line of organic health and wellness...Relevium Executes LOI to Acquire Montreal Biopharma Contract Manufacturing Company
by Olga Tkach | November 8, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a letter of intent to acquire a Montreal based biopharma contract...Relevium Technologies
Relevium is a publicly traded corporation strategically focused on the expansion and acquisition of entrepreneurial brands within the health and wellness sector. Our focus is on being a trusted source of high-quality nutraceutical and CBD products.contact us
Relevium Technologies Inc.
1000 Sherbrooke West, Suite 2700
Montreal, QC, H3A 3G4
(888) 528-8687
www.releviumtechnologies.com
info@releviumtechnologies.com
trading information
Market data is delayed by 15 minutes
Relevium Reports Interim First Quarter Results for the Three-Month Period Ended September 30, 2020
by Olga Tkach | January 25, 2021 | 2021 Press Releases | 0 Comments
MONTREAL, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report the completion of the interim financial statements and MD&A for the three-month period ended...Relevium Reports Fiscal Year Ended June 30, 2020 Results
by Olga Tkach | January 20, 2021 | 2021 Press Releases | 0 Comments
MONTREAL, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report the completion of the financial audit for the fiscal year ended June 30, 2020. The Company’s...Relevium Issues Corporate Update on MCTO and Filing of Financial Statements
by Olga Tkach | January 6, 2021 | 2021 Press Releases | 0 Comments
MONTREAL, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) announces an update on its ongoing disclosure obligations and to its previously disclosed management cease trade...